Cover Image
Market Research Report

ASIA PACIFIC DRUG DISCOVERY MARKET FORECAST 2018-2026

Published by Inkwood Research Product code 609207
Published Content info 87 Pages
Delivery time: 1-2 business days
Price
Back to Top
ASIA PACIFIC DRUG DISCOVERY MARKET FORECAST 2018-2026
Published: March 2, 2018 Content info: 87 Pages
Description

KEY FINDINGS

The Asia Pacific drug discovery market t is predicted to exhibit a CAGR of 10.40%.

MARKET INSIGHTS

China is the most lucrative market for drug discovery in APAC. Over 80% of the Chinese pharmaceutical market is into generic drugs. That percentage is multiple times higher than a developed country like the U.S. Also, innovations in China are significantly improving. Over the past few years, the Indian pharmaceutical companies, too, have been attempting to re-orientate their efforts toward developing new innovative medicines. By exhibiting the highest CAGR between 2018-2026, the Australian drug discovery market is expected to attract major global market players. Compared to other APAC countries, the level of awareness amongst Australians regarding various health issues is much higher.

COMPETITIVE INSIGHTS

Bayer Ag, Sanofi, AstraZeneca Plc, Eli Lily, Pfizer Inc, Merck & Co. Inc, GlaxoSmithKline Llc, Boehringer Ingelheim, F. Hoffmann-La Roche Ltd and Johnson and Johnson are some of the leading players in this market.

Table of Contents
Product Code: 13801

Table of Contents

1. RESEARCH SCOPE

  • 1.1. STUDY GOALS
  • 1.2. SCOPE OF THE MARKET STUDY
  • 1.3. WHO WILL FIND THIS REPORT USEFUL?
  • 1.4. STUDY AND FORECASTING YEARS

2. RESEARCH METHODOLOGY

  • 2.1. SOURCES OF DATA
    • 2.1.1. SECONDARY DATA
    • 2.1.2. PRIMARY DATA
  • 2.2. TOP DOWN APPROACH
  • 2.3. BOTTOM-UP APPROACH
  • 2.4. DATA TRIANGULATION

3. EXECUTIVE SUMMARY

  • 3.1. MARKET SUMMARY
  • 3.2. KEY FINDINGS
    • 3.2.1. HIGH PREVALENCE RATE OF MAJOR HEALTH DISORDERS
    • 3.2.2. IMPLEMENTATION OF DRUG DISCOVERY PROGRAMS

4. MARKET DETERMINANTS

  • 4.1. MARKET DRIVERS
    • 4.1.1. AGING POPULATION
    • 4.1.2. BRANDED DRUGS ARE OUTPERFORMING DUE TO HIGH COST AS COMPARED TO GENERIC DRUGS
    • 4.1.3. SPENDING ON HEALTHCARE HAS INCREASED
  • 4.2. MARKET RESTRAINTS
    • 4.2.1. GOVERNMENT REGULATIONS DELAYING THE PROCESSES
    • 4.2.2. DELAY IN PRODUCT LAUNCHES
    • 4.2.3. POOR ACCESS TO THE HEALTHCARE SERVICES IN DEVELOPING MARKETS
    • 4.2.4. MARKET IS SHIFTING FROM BRANDED TO GENERIC DRUGS
  • 4.3. MARKET CHALLENGES
    • 4.3.1. COST BARRIER FOR LOCAL PEOPLE IN EMERGING ECONOMIES
  • 4.4. MARKET OPPORTUNITIES
    • 4.4.1. EXTENSIVE R & D FOR NEW PRODUCT LAUNCHES

5. MARKET SEGMENTATION

  • 5.1. MARKET BY TECHNOLOGY 2018-2026
    • 5.1.1. QPCR
    • 5.1.2. DNA MICROARRAYS
    • 5.1.3. PROTEIN MICROARRAYS
    • 5.1.4. HIGH-THROUGHPUT SCREENING
    • 5.1.5. MASS SPECTROMETRY
    • 5.1.6. GEL ELECTROPHORESIS
    • 5.1.7. CHROMATOGRAPHY
    • 5.1.8. PROTEIN AND NUCLEIC ACID ISOLATION
    • 5.1.9. OTHER TECHNOLOGIES

6. KEY ANALYTICS

  • 6.1. PORTER'S FIVE FORCES ANALYSIS
    • 6.1.1. THREATS OF NEW ENTRANTS(LOW)
    • 6.1.2. COMPETITIVE RIVALRY (HIGH)
    • 6.1.3. BARGAINING POWER OF BUYERS (MEDIUM)
    • 6.1.4. BARGAINING POWER OF SUPPLIERS (LOW)
    • 6.1.5. THREAT OF SUBSTITUTE PRODUCTS (HIGH)
  • 6.2. VALUE CHAIN ANALYSIS
  • 6.3. KEY EXCERPTS OF THE STUDY
    • 6.3.1. RELAXATION IN REGULATIONS BY THE GOVERNMENT WHICH STOPS RESEARCHERS FROM DOING RESEARCH
    • 6.3.2. MARKET LEADERS SHOULD OPEN UP THEIR BRANCHES AND RESEARCH LABS IN EMERGING MARKETS.
  • 6.4. PESTLE ANALYSIS
  • 6.5. OPPORTUNITY MATRIX

7. GEOGRAPHICAL ANALYSIS

  • 7.1. ASIA PACIFIC
    • 7.1.1. INDIA
    • 7.1.2. CHINA
    • 7.1.3. JAPAN
    • 7.1.4. KOREA
    • 7.1.5. AUSTRALIA
    • 7.1.6. REST OF ASIA-PACIFIC (ROAPAC)

8. COMPANY PROFILES

  • 8.1. ASTRAZENECA PLC
    • 8.1.1. COMPANY OVERVIEW
    • 8.1.2. PRODUCT PORTFOLIO
    • 8.1.3. SWOT ANALYSIS
    • 8.1.4. STRATEGIC INITIATIVES
  • 8.2. BAYER AG
    • 8.2.1. COMPANY OVERVIEW
    • 8.2.2. PRODUCT PORTFOLIO
    • 8.2.3. SWOT ANALYSIS
    • 8.2.4. STRATEGIC INITIATIVES
  • 8.3. BOEHRINGER INGELHEIM
    • 8.3.1. COMPANY OVERVIEW
    • 8.3.2. PRODUCT PORTFOLIO
    • 8.3.3. SWOT ANALYSIS
  • 8.4. ELI LILY
    • 8.4.1. COMPANY OVERVIEW
    • 8.4.2. PRODUCT PORTFOLIO
    • 8.4.3. SWOT ANALYSIS
    • 8.4.4. STRATEGIC INITIATIVES
  • 8.5. F. HOFFMANN-LA ROCHE LTD
    • 8.5.1. COMPANY OVERVIEW
    • 8.5.2. PRODUCT PORTFOLIO
    • 8.5.3. SWOT ANALYSIS
    • 8.5.4. STRATEGIC INITIATIVES
  • 8.6. GLAXOSMITHKLINE LLC
    • 8.6.1. COMPANY OVERVIEW
    • 8.6.2. PRODUCT PORTFOLIO
    • 8.6.3. SWOT ANALYSIS
    • 8.6.4. STRATEGIC INITIATIVES
  • 8.7. JOHNSON AND JOHNSON
    • 8.7.1. COMPANY OVERVIEW
    • 8.7.2. PRODUCT PORTFOLIO
    • 8.7.3. SWOT ANALYSIS
    • 8.7.4. STRATEGIC INITIATIVES
  • 8.8. MERCK & CO. INC.
    • 8.8.1. COMPANY OVERVIEW
    • 8.8.2. PRODUCT PORTFOLIO
    • 8.8.3. SWOT ANALYSIS
    • 8.8.4. STRATEGIC INITIATIVES
  • 8.9. PFIZER, INC.
    • 8.9.1. COMPANY OVERVIEW
    • 8.9.2. SWOT ANALYSIS
    • 8.9.3. STRATEGIC INITIATIVES
  • 8.10. SANOFI
    • 8.10.1. COMPANY OVERVIEW
    • 8.10.2. PRODUCT PORTFOLIO
    • 8.10.3. SWOT ANALYSIS
    • 8.10.4. STRATEGIC INITIATIVES

TABLE LIST

  • TABLE 1 ASIA PACIFIC DRUG DISCOVERY MARKET 2018-2026 (IN $MILLION)
  • TABLE 2 ASIA PACIFIC DRUG DISCOVERY MARKET, BY TECHNOLOGY 2018-2026
  • TABLE 3 ASIA PACIFIC DRUG DISCOVERY MARKET IN QPCR 2018-2026 (IN $MILLION)
  • TABLE 4 ASIA PACIFIC DRUG DISCOVERY MARKET IN DNA MICROARRAYS 2018-2026 (IN $MILLION)
  • TABLE 5 ASIA PACIFIC DRUG DISCOVERY MARKET IN PROTEIN MICROARRAYS, 2018-2026(IN $MILLION)
  • TABLE 6 ASIA PACIFIC DRUG DISCOVERY MARKET IN HIGH THROUGHPUT SCREENING, 2018-2026(IN $MILLION)
  • TABLE 7 ASIA PACIFIC DRUG DISCOVERY MARKET IN MASS SPECTROMETRY, 2018-2026(IN $MILLION)
  • TABLE 8 ASIA PACIFIC DRUG DISCOVERY MARKET IN GEL ELECTROPHORESIS, 2018-2026, (IN $MILLION)
  • TABLE 9 ASIA PACIFIC DRUG DISCOVERY MARKET IN CHROMATOGRAPHY, 2018-2026 (IN $MILLION)
  • TABLE 10 ASIA PACIFIC DRUG DISCOVERY MARKET IN PROTEIN AND NUCLEIC ACID ISOLATION, 2018-2026 (IN $MILLION)
  • TABLE 11 ASIA PACIFIC DRUG DISCOVERY MARKET IN OTHER TECHNOLOGIES MARKET, 2018-2026 (IN $MILLION)
  • TABLE 12 ASIA PACIFIC DRUG DISCOVERY MARKET, 2018-2026 (IN $MILLION)
  • FIGURE LIST
  • FIGURE 1 ASIA PACIFIC DRUG DISCOVERY MARKET 2018-2026 (IN $MILLION)
  • FIGURE 2 ASIA PACIFIC DRUG DISCOVERY MARKET IN QPCR 2018-2026 (IN $MILLION)
  • FIGURE 3 ASIA PACIFIC DRUG DISCOVERY MARKET IN DNA MICROARRAYS 2018-2026 (IN $MILLION)
  • FIGURE 4 ASIA PACIFIC DRUG DISCOVERY MARKET IN PROTEIN MICROARRAYS 2018-2026 (IN $MILLION)
  • FIGURE 5 ASIA PACIFIC DRUG DISCOVERY MARKET IN HIGH THROUGHPUT SCREENING 2018-2026 (IN $MILLION)
  • FIGURE 6 ASIA PACIFIC DRUG DISCOVERY MARKET IN MASS SPECTROMETRY 2018-2026 (IN $MILLION)
  • FIGURE 7 ASIA PACIFIC DRUG DISCOVERY MARKET IN GEL ELECTROPHORESIS 2018-2026 (IN $MILLION)
  • FIGURE 8 ASIA PACIFIC DRUG DISCOVERY MARKET IN CHROMATOGRAPHY 2018-2026 (IN $MILLION)
  • FIGURE 9 ASIA PACIFIC DRUG DISCOVERY MARKET IN PROTEIN AND NUCLEIC ACID ISOLATION 2018-2026 (IN $MILLION)
  • FIGURE 10 ASIA PACIFIC DRUG DISCOVERY MARKET IN OTHER TECHNOLOGIES 2018-2026 (IN $MILLION)
  • FIGURE 11 ASIA PACIFIC DRUG DISCOVERY MARKET, 2018-2026 (IN $MILLION)
  • FIGURE 12 INDIA DRUG DISCOVERY MARKET, 2018-2026 (IN $MILLION)
  • FIGURE 13 CHINA DRUG DISCOVERY MARKET, 2018-2026 (IN $MILLION)
  • FIGURE 14 JAPAN DRUG DISCOVERY MARKET, 2018-2026 (IN $MILLION)
  • FIGURE 15 KOREA DRUG DISCOVERY MARKET, 2018-2026 (IN $MILLION)
  • FIGURE 16 AUSTRALIA DRUG DISCOVERY MARKET, 2018-2026 (IN $MILLION)
  • FIGURE 17 REST OF ASIA-PACIFIC (ROAPAC) DRUG DISCOVERY MARKET, 2018-2026 (IN $MILLION)
Back to Top